New clinical data shows that Calocurb, a 100 percent natural GLP-1 triple hormone activator, enabled an average weight loss of 8.3lbs over six months while preserving muscle mass. The oral twice-daily capsule uses bitter hops extract Amarasate to stimulate satiety hormones and reduce visceral fat…
A 100 percent natural GLP-1 triple hormone activator has demonstrated the ability to reduce body fat while maintaining muscle mass, according to newly released clinical data. The nutraceutical, Calocurb, was the subject of a study that tracked participants over a 24 week period. Those taking the supplement achieved an average weight loss of 8.3 pounds after six months when combined with standard healthy diet and exercise advice. In comparison, the placebo group did not show the same level of fat reduction or muscle preservation.
These results are noteworthy because synthetic GLP-1 drugs, such as semaglutide, often lead to a decrease in muscle mass even as they reduce body fat. Calocurb provides a non-prescription alternative in the form of an oral twice daily capsule. The product is already available in the United States and is used by both practitioners and consumers, according to the company.
The active ingredient in Calocurb is Amarasate, a bitter hops extract. This compound interacts with bitter taste receptors TAS2Rs located in the small intestine. The interaction triggers the release of three natural satiety hormones: GLP-1, CCK, and PYY. Each of these hormones plays a distinct role. GLP-1 and CCK both promote feelings of fullness, while CCK also encourages fat oxidation and PYY supports the preservation of muscle tissue.
Earlier research on Calocurb showed additional appetite related benefits. In one hour after taking the supplement, participants experienced a 30 percent reduction in appetite, a 40 percent decrease in cravings, and an 18 percent lower average caloric intake. The latest clinical study also reported that over the full 24 weeks, the treatment led to a 3.5 times greater reduction in visceral fat compared to the placebo group.
Sarah Kennedy, Founder and CEO of Calocurb, commented directly on the new findings. She said, “The new clinical data proves not only Calocurb’s contribution to weight loss overall, but also muscle preservation, which is groundbreaking in the crowded space of GLP-1s and other weight reduction options.” The company positions Calocurb as a differentiated approach in the competitive obesity drug market, leveraging natural mechanisms rather than synthetic compounds.
The broader market for GLP targeting obesity treatments continues to evolve rapidly. In April of the same year, Boehringer Ingelheim released data highlighting the potential of survodutide, which is described as the first global glucagon/GLP-1 dual agonist GLP1-RA . That candidate represents another step beyond single hormone targeting.
Earlier in January, Roche disclosed Phase II findings for its own dual GLP-1 receptor agonist. The company’s once weekly subcutaneous injectable, CT-388, achieved resolution of obesity in 54 percent of trial participants. This data suggests strong efficacy for injectable GLP therapies.
Most recently, Eli Lilly expanded its GLP portfolio through a licensing deal with Hanmi Pharm. The agreement, announced last month, is for a novel long acting glucagon-like peptide 2 GLP-2 biologic. The total potential value of the deal is $1.26 billion, indicating significant commercial interest in this class of medicines.
Calocurb’s natural triple hormone activator thus enters a field filled with synthetic and injectable options. Its ability to preserve muscle while reducing fat may appeal to those seeking a non prescription, oral alternative that works with the body’s own hormone systems.
Peptides referenced: Semaglutide, Survodutide, Glucagon, GLP-1.
Related reading: Why GLP-1 Coverage is Important for Menopause, Developing Nutraceutical Solutions for Long-Term GLP-1 Patient Support, GLP-1 Drug Uptake Accelerates as Food Makers Adapt Products, GLP-1 Drugs Linked to Hair Loss in New Study.